Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Sun Pharma Canada
Prednisolone is a synthetic adrenocortical glucocorticoid that binds and activates nuclear glucocorticoid receptors, altering gene expression to suppress inflammatory processes and lymphocyte numbers. It is used in ophthalmic, dermatologic, allergic, endocrine, hematologic, gastrointestinal and neoplastic conditions, and is studied in lymphoma, leukemia, prostate cancer and other settings.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 23, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05023304 | Phase 4 | Cataract | Completed | OCUL |
| NCT07365995 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Recruiting | BNTX |
| NCT06091254 | Phase 3 | Follicular Lymphoma (FL) | Recruiting | REGN |
| NCT05139316 | Phase 3 | Glycogen Storage Disease Type IA | Completed | RARE |
| NCT07387926 | Phase 1/2 | Acute Lymphoblastic Leukemia | Recruiting | NVS |
| NCT07190300 | Phase 1/2 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Recruiting | NVS |
| NCT02904772 | Phase 2 | LPL Deficiency | Withdrawn | QURE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Lymphoblastic LeukemiaDiffuse Large B-cell Lymphoma (DLBCL)Follicular LymphomaLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveMetastatic Castration-resistant Prostate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)CataractGlycogen Storage Disease Type IALPL Deficiency
Updated Nov 15, 2026.